The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of the WEE1 inhibitor AZD1775 in SETD2-deficient advanced solid tumor malignancies.
 
Edward Maldonado
No Relationships to Disclose
 
Wendy Kimryn Rathmell
Stock and Other Ownership Interests - Caribou Biosciences (I); Nirogy Therapeutics (I); Sitryx (I)
Consulting or Advisory Role - Caribou Biosciences (I); Nirojy (I); Sitryx (I)
Research Funding - Incyte (I); Peloton Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - ClearCode34 Risk prediction biomarker for kidney cancer; hERV 3-2 expression as a biomarker of response to immunotherapy
 
Geoffrey Shapiro
Consulting or Advisory Role - Artios; Atrin Pharmaceuticals; Bayer; Bicycle Therapeutics; Blueprint Medicines; Boehringer Ingelheim; Concarlo; Cybrexa Therapeutics; CytomX Therapeutics; Fusion Pharmaceuticals; ImmunoMet; Janssen Oncology; Kymera; Lilly; Merck Serono; Pfizer; Syros Pharmaceuticals; Xinthera; Zentalis
Research Funding - Abbvie (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Biosplice (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb/Medarex (Inst); CanBas (Inst); Cellceutix (Inst); Clovis Oncology (Inst); Cyclacel (Inst); Cyteir (Inst); Esperas Pharma (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Senhwa Biosciences (Inst); Sierra Oncology (Inst); Syros Pharmaceuticals (Inst); Tango Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Patent #: 9872874 Title: Dosage regimen for sapacitabine and seliciclib Issue Date: 1/23/2018; Provisional Patent #:62/538,319 Title: Compositions and methods for predicting response and resistance to CDK4/6 inhibition Filed: 7/28/17
 
Jordi Rodon Ahnert
Consulting or Advisory Role - AADi; Avoro Capital Advisors; Boxer Capital; Chinese University of Hong Kong; Clarion Healthcare; Columbus Venture Partners; Cullgen; Debiopharm Group; Ellipses Pharma; Envision Pharma Group; iOnctura; Macrogenics; Merus; Monte Rosa Therapeutics; Monte Rosa Therapeutics; Oncology One; Pfizer; Sardona Therapeutics; Tang Advisors; Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social
Research Funding - AADi (Inst); Amgen (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Cellestia Biotech (Inst); Curis (Inst); CytomX Therapeutics (Inst); Deciphera (Inst); Fore Biotherapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Hummingbird (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Kelun (Inst); Linnaeus Therapeutics (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Nuvation Bio (Inst); Pfizer (Inst); Roche (Inst); Spectrum Pharmaceuticals (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Takeda/Millennium (Inst); Tango Therapeutics (Inst); Vall d'Hebron Institute of Oncology/Cancer Core Europe (Inst); Yingli Pharma (Inst)
Travel, Accommodations, Expenses - ESMO
Other Relationship - Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social
 
Devalingam Mahalingam
Consulting or Advisory Role - Amgen; OncoOne; Qurient
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Eisai; Exelixis; Genentech
Research Funding - Merck KGaA; Oncolytics
 
Nikolaos Trikalinos
Research Funding - Bristol-Myers Squibb (Inst); Elevar Therapeutics (Inst); Exelixis (Inst); Merck (Inst); Novartis (Inst); Nykode Therapeutics (Inst)
 
Arash Rezazadeh
Stock and Other Ownership Interests - ECOM Medical
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; EMD Serono; Exelixis; Genentech; Gilead Sciences; Immunomedics; Novartis; Pfizer
Speakers' Bureau - Amgen; Astellas Medivation; AstraZeneca; AVEO; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Exelixis; Genentech/Roche; Gilead Sciences; Gilead Sciences; Janssen; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Seattle Genetics/Astellas; Seattle Genetics/Astellas
Research Funding - Amgen (Inst); Arvinas (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); BeyondSpring Pharmaceuticals (Inst); BioClin Therapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Epizyme (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Janssen (Inst); Macrogenics (Inst); Merck (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); POINT Biopharma (Inst); POINT Biopharma (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Astellas Medivation; AstraZeneca; Bayer; Eisai; Exelixis; Genentech; Janssen; Novartis; Pfizer; Prometheus
 
Victor Ricardo Adorno Febles
No Relationships to Disclose
 
Mamta Parikh
Consulting or Advisory Role - AstraZeneca; Bristol Myers Squibb; Exelixis; Natera; OncoCyte; Seagen
Research Funding - Karyopharm Therapeutics
 
Scott Anthony Boerner
No Relationships to Disclose
 
Gregor Krings
No Relationships to Disclose
 
Naoko Takebe
No Relationships to Disclose
 
Patricia LoRusso
Stock and Other Ownership Interests - BAKX Therapeutics
Honoraria - Five Prime Therapeutics
Consulting or Advisory Role - Abbvie; ABL Bio; Agenus; Agios; Astellas Pharma; AstraZeneca; BAKX Therapeutics; Bayer; Black Diamond Therapeutics; Compass Therapeutics; Cybrexa Therapeutics; CytomX Therapeutics; EMD Serono; Five Prime Therapeutics; Genentech; Genmab; GlaxoSmithKline; Halozyme; I-Mab; ImCheck therapeutics; ImmunoMet; IQvia; Kineta; Kyowa Kirin International; Macrogenics; Mekanistic Therapeutics; Molecular Templates; Molecular Templates; Neurotrials Research; Pfizer; QED Therapeutics; Qualigen Therapeutics; Relay Therapeutics; Roche/Genentech; Roivant; Salarius Pharmaceuticals; Scenic Biotech; Seagen; Shattuck Labs; Silverback Therapeutics; SK Life Sciences; Sotio; ST Cube; Stemline Therapeutics; Takeda; Trial to Reduce IDDM in the Genetically at Risk (TRIGR); TYME; Zentalis
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Genentech
 
Rahul Raj Aggarwal
Consulting or Advisory Role - Advanced Accelerator Applications; Alessa Therapeutics; Amgen; Bayer; Dendreon; Exelixis; Jubilant Pharmaceuticals; Merck; OncLive.; OncLive.; Pfizer; Tersera
Research Funding - Amgen (Inst); AstraZeneca (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Xynomic Pharma (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - DAVA Oncology